Skip to main content
SpringerLink
Log in
Book cover

Molecular Basis of Thyroid Cancer pp 317–343Cite as

Thyroid Cancer Imaging

  • Chapter

Part of the Cancer Treatment and Research book series (CTAR,volume 122)

Keywords

  • Thyroid Cancer
  • Thyroid Carcinoma
  • Medullary Thyroid Carcinoma
  • Medullary Thyroid
  • Differentiate Thyroid Cancer

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Delange F. Iodine deficiency in Europe and its consequences: an update. Eur J Nucl Med Mol Imaging 2002; 29, suppl 2:S404–S16.

    CAS  PubMed  Google Scholar 

  2. Delange F., van Onderbergen A., Shabana W., Vandemeulebroucke E., Vertongen F., Gnat D., Dramaix M. Silent iodine profylaxis in Western Europe only partly corrects iodine deficiency; the case of Belgium. Eur J Endocrinol 2000; 143:189–96.

    CrossRef  CAS  PubMed  Google Scholar 

  3. European Commission: Health & Consumer Protection Directorate-General. Opinion of the Scientific Committee on Food on the tolerable upper intake level of iodine.2002. B-1049 Bruxelles Belgium. http://www.europa.eu.int/comm./food/fs/sc/scf/indexe.html.

  4. Berne R.M., Levy M.N. Physiology. Mosby Year Book, Missouri, USA. Third edition 1993: p932–937.

    Google Scholar 

  5. Yoshida A., Taniguchi S., Hisatome I., Royaux I.E., Green E.D., Kohn L.D., Suzuki K. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 2002; 87:3356–61.

    CAS  PubMed  Google Scholar 

  6. Kondo T., Nakamura N., Suzuki K., Murata S., Muramatsu A., Kawaoi A., Katoh R. Expression of human pendrin in diseased thyroids. J Histochem Cytochem 2003; 51:167–73.

    CAS  PubMed  Google Scholar 

  7. Bidart J.M., Mian C., Lazar V., Russo D., Filetti S., Caillou B., Schlumberger M. Expression of pendrin and the Pendred Syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab 2000; 85:2028–33.

    CAS  PubMed  Google Scholar 

  8. Porra V., Bernier-Valentin F., Trouttet-Masson S., Berger-Dutrieux N., Peix J.L., Perrin A., Sehni-Ruby S., Rousset B. Characterization and semiquantitative analyses of pendrin expressed in normal and tumoral human thyroid tissues. J Clin Endocrinol Metab 2002; 87:1700–07.

    CrossRef  CAS  PubMed  Google Scholar 

  9. Klain M., Ricard M., Leboulleux S., Baudin E., Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29 suppl 2:S479–S85.

    CAS  PubMed  Google Scholar 

  10. Pentlow K.S., Graham M.C., Lambrecht R.M., Daghighian F., Bacharach S.L., Bendriem B., Finn R.D., Jordan K., Kalaigian H., Karp J.S., Robeson W.R., Larson S.M. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996; 37:1557–62.

    CAS  PubMed  Google Scholar 

  11. Eschmann S.M., Reischl G., Bilger K., Kupferschlager J., Thelen M.H., Dohmen B.M., Besenfelder H., Bares R. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002; 29:760–7.

    CrossRef  CAS  PubMed  Google Scholar 

  12. Crawford D.C., Flower M.A., Pratt B.E., Hill C., Zweit J., McCready VR., Harmer C.L. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med 1997; 24:1470–8.

    CrossRef  CAS  PubMed  Google Scholar 

  13. Flower M.A., al-Saadi A., Harmer C.L., McCready V.R., Ott R.J. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med. 1994; 21:531–6.

    CrossRef  CAS  PubMed  Google Scholar 

  14. Frey P., Townsend D., Jeavons A., Donath A. In vivo imaging of the human thyroid with a positron camera using 124I. Eur J Nucl Med. 1985; 10:472–6.

    CrossRef  CAS  PubMed  Google Scholar 

  15. Frey P., Townsend D., Flattet A., De Gautard R., Widgren S., Jeavons A., Christin A., Smith A., Long A., Donath A. Tomographic imaging of the human thyroid using 124I. J Clin Endocrinol Metab 1986; 63:918–27.

    CAS  PubMed  Google Scholar 

  16. Freudenberg L.S., Antoch G., Gorges R., Knust J., Pink R., Jentzen W., Debatin J.F., Brandau W., Bockisch A., Stattaus J. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003; May 8 [Epub ahead of print].

    Google Scholar 

  17. Ladenson P.W. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000; 30:98–106.

    CAS  PubMed  Google Scholar 

  18. Chin B.B., Patel P., Cohade C., Ewertz M., Wahl R., Ladenson P. Recombinant human thyrotropin stimulaton of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:91–5.

    CrossRef  CAS  PubMed  Google Scholar 

  19. Mazzaferri E.L., Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol 2001; 86:1447–63.

    CAS  Google Scholar 

  20. Mazzaferri E.L., Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endoc-Relat Cancer 2002; 9:227–47.

    CAS  Google Scholar 

  21. Toft A., Beckett G. Use of recombinant thyrotropin. Lancet 2002; 359:1874–5.

    PubMed  Google Scholar 

  22. Shapiro B., Rufini V., Jarwan A., Geatti O., Kearfott K.J., Fig L.M., Kirkwood I.D., Gross M.D. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Sem Nucl Med 2000; 30:115–32.

    CAS  Google Scholar 

  23. Carlisle M.R., Lu C., McDougall I.R. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Comm 2003; 24:715–5.

    CAS  Google Scholar 

  24. de Klerk J.M., de Keizer B., Zelissen P.M., Lips C.M., Koppeschaar H.P. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nucl Med Comm 2000; 21:529–32.

    Google Scholar 

  25. Cailleux A.F., Baudin E., Travagli J.P., Ricard M., Schlumberger M. Is diagnostic iodine-131 scanning useful after thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85:175–8.

    CrossRef  CAS  PubMed  Google Scholar 

  26. Pacini F., Capezzone M., Elisei R., Ceccarelli C., Taddei D., Pinchera A. Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499–1501.

    CAS  PubMed  Google Scholar 

  27. Pacini F., Molinaro E., Castagna M.G., Lippi F., Ceccarelli C., Agate L., Elisei R., Pinchera A. Ablation of the thyroid residues with 30 mCi (131)I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063–8.

    CAS  PubMed  Google Scholar 

  28. Cholewinski S.P., Yoo K.S., Klieger P.S., O’Mara R.E. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 1311. J Nucl Med 2000; 41:1198–1202.

    CAS  PubMed  Google Scholar 

  29. Pacini F., Lippi F., Formica N., Elisei R., Anelli S., Cecccarelli C., Pinchera A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987; 8:1888–91.

    Google Scholar 

  30. Fatourechi V., Hay I.D., Mulan D.P., Wiseman G.A., Eghbali-Fatourechi G.Z., Thorson L.M., Gorman C.A. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10:573–77.

    CAS  PubMed  Google Scholar 

  31. Mazzaferri E.L. Long-termoutcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6:469–76.

    CAS  PubMed  Google Scholar 

  32. Sabri O., Zimny M., Schreckenberger M., Meyer-Oelman A., Reinartz P., Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000; 27:1591–7.

    CrossRef  CAS  PubMed  Google Scholar 

  33. Coakley A.J. Thyroid stunning. Eur J Nucl Med 1998; 25:203–4.

    CrossRef  CAS  PubMed  Google Scholar 

  34. Van Tol K.M. New insights in diagnosis and treatment of differentiated thyroid carcinoma. Thesis 2002. State University Groningen (a).

    Google Scholar 

  35. Robbins R.J., Tuttle R.M., Sharaf R.N., Larson S.M., Robbins H.K., Ghossein R.A., Smith A., Drucker W.D. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:619–25.

    CrossRef  CAS  PubMed  Google Scholar 

  36. Robbins R.J., Larson S.M., Sinha N., Shaha A., Divgi C., Pentlow K.S., Ghossein R., Tuttle R.M. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002; 43:1482–88.

    CAS  PubMed  Google Scholar 

  37. Barbaro D., Boni G., Meucci G., Simi U., Lapi P., Orsini P., Pasquini C., Piazza F., Caciagli M., Mariani G. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88:4110–5.

    CrossRef  CAS  PubMed  Google Scholar 

  38. Menzel C., Kranert, Dorbert N., Diehl M., Fietz T., Hamscho N., Berner U., Grunwald F. RhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. J Nucl Med 2003; 44:1065–68.

    CAS  PubMed  Google Scholar 

  39. Wartofsky L. Editorial: Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic 131I scanning. J Clin Endocrinol Metab 2002; 87:1486–89.

    CrossRef  CAS  PubMed  Google Scholar 

  40. Mazzaferri E.L., Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490–98.

    CrossRef  CAS  PubMed  Google Scholar 

  41. Sherman S.I. Thyroid carcinoma. Lancet 2003; 361:501–11.

    PubMed  Google Scholar 

  42. Williams J.A., Berens S.C., Wolff J. Thyroid secretion in vitro: inhibition of TSH and dibutyryl cyclic-AMP stimulated (131I) release by lithium. Endocrinology 1971; 88:1385–88.

    CAS  PubMed  Google Scholar 

  43. Koong S.S., Reynolds J.C., Movius E.G., Keenan A.M., Ain K.B., Lakshmanan M.C., Robbins J. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912–16.

    CrossRef  CAS  PubMed  Google Scholar 

  44. Simon D., Koehrle J., Reiners C., Boemer A.R., Schmutzler C., Mainz K., Goretzki P.E., Roeher H.D. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22:569–74.

    CAS  PubMed  Google Scholar 

  45. Schmutzler C., Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000; 10:393–406.

    CAS  PubMed  Google Scholar 

  46. Gruning T., Tiepolt C., Zophel K., Bredow J., Kropp J., Franke W.G. Retinoic acid for redifferentiation of thyroid cancer: does it hold its promise? Eur J Endocrinol 2003; 148:395–402.

    CrossRef  CAS  PubMed  Google Scholar 

  47. Chung J.K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43:1188–1200.

    CAS  PubMed  Google Scholar 

  48. Filetti S., Bidart J.M., Arturi F., Caillou B., Russo D., Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999; 141:443–57.

    CrossRef  CAS  PubMed  Google Scholar 

  49. Ozata M., Suzuki S., Miyamoto T., Liu R.T., Fierro-Renoy F., DeGroot L.J. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79:98–105.

    CrossRef  CAS  PubMed  Google Scholar 

  50. Schlumberger M., Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid cancer. Eur J Endocrinol 1998; 138:249–52.

    CrossRef  CAS  PubMed  Google Scholar 

  51. Mazzaferri E.L. Treating high thyroglobulin with radioiodine: A magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995; 80:1485–7.

    CrossRef  CAS  PubMed  Google Scholar 

  52. Schlumberger M., Mancusi F., Baudin E., Pacini F. 131-I therapy for elevated thyroglobulin levels. Thyroid 1997; 7:273–6.

    CAS  PubMed  Google Scholar 

  53. Pacini F., Agate L., Elisei R., Capezzone M., Ceccarelli C., Lippi F., Molinaro E. & Pinchera A. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: Comparison of patients treated with high 131I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86:4092–7.

    CAS  PubMed  Google Scholar 

  54. Schlumberger M., Arcangioli O., Pierkaski J.D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29:1790–4.

    CAS  PubMed  Google Scholar 

  55. Pineda J.D., Lee T., Ain K., Reynolds J.C. & Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488–92.

    CrossRef  CAS  PubMed  Google Scholar 

  56. de Keizer B., Koppeschaar H.P.F., Zelissen P.M.J., Lips C.J.M., van Rijk R.P., van Dijk A., de Klerk J.M.H. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. European Journal of Nuclear Medicine 2001; 281:198–202.

    Google Scholar 

  57. McDougall I.R. 131-I treatment of 131-I negative whole body scans, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997; 7:669–72.

    CAS  PubMed  Google Scholar 

  58. Fatourechi V., Hay I.D., Javedan H., Wiseman G.A., Mullan B. & Gorman C.A. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002; 87:1521–26.

    CAS  PubMed  Google Scholar 

  59. Schaap J., Eustatia-Rutten C.F.A., Stokkel M., Links T.P., Diamant M., van der Velde E., Romijn J.A., Smit J.W.A. Does radioiodine therapy have disadvantageous effects in non-radioiodine accumulating differentiated thyroid cancer? Clin Endocrinol 2002; 57:117–24.

    CrossRef  CAS  Google Scholar 

  60. Van Tol K.M., Jager P.L., De Vries E.G.E., Piers D.A., Boezen H.M., Sluiter W.J., Dullaart R.P.F., Links T.P. Outcome in patients with differentiated thyroid cancer with negative whole body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003; 148:589–96.

    PubMed  Google Scholar 

  61. Warburg O. The metabolism of tumors. New York, NY: Richard R. Smith. 1931:129–6.

    Google Scholar 

  62. Brown R.S., Goodman T.M., Zasadny K.R., Greenson J.K., Wahl R.L. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol. 2002; 29:443–53.

    CAS  PubMed  Google Scholar 

  63. Higashi T., Saga T., Nakamoto Y., Ishimori T., Mamede M.H., Wada M., Doi R., Hosotani R., Imamura M., Konishi J. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002; 43:173–80.

    CAS  PubMed  Google Scholar 

  64. Muzi M., Freeman S.D., Burrows R.C., Wiseman R.W., Link J.M., Krohn K.A., Graham M.M., Spence A.M., Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. Nucl Med Biol 2001; 28:107–16.

    CAS  PubMed  Google Scholar 

  65. Smith T.A. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000; 57:170–8.

    CAS  PubMed  Google Scholar 

  66. Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972–80.

    CAS  PubMed  Google Scholar 

  67. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409–15.

    CAS  PubMed  Google Scholar 

  68. Wieler H.J., Coleman R.E. PET in Clinical Oncology. Springer, Steinkopff Verlag, Darmstadt, Germany. 2000 17–62.

    Google Scholar 

  69. Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987; 28:910–4.

    CAS  PubMed  Google Scholar 

  70. Hooft L., Hoekstra O.S., Deville W., Lips P., Teule G.J., Boers M., van Tulder M.W. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:3779–86.

    CrossRef  CAS  PubMed  Google Scholar 

  71. Van Tol K.M., Jager P.L. Piers D.A., Pruim J., De Vries E.G.E., Dullaart R.P.F., Links T.P. Better yield of 18Fluorodeoxyglucose-Positron Emission Tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002; 12:381–7.

    PubMed  Google Scholar 

  72. Petrich T., Borner A.R., Otto D., Hofmann M., Knapp W.H. Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002; 29:641–7.

    CAS  Google Scholar 

  73. James C., Starks M., MacGillivray D.C., White J. The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. Surg Oncol Clin N Am 1999; 8:145–69.

    CAS  PubMed  Google Scholar 

  74. Diehl M., Risse J.H., Brandt-Mainz K., Dietlein M., Bohuslavizki K.H., Matheja P., Lange H., Bredow J., Korber C., Grunwald F. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001; 28:1671–6.

    CrossRef  CAS  PubMed  Google Scholar 

  75. Szakall S. Jr., Esik O., Bajzik G., Repa I., Dabasi G., Sinkovics I., Agoston P., Tron L. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43:66–71.

    PubMed  Google Scholar 

  76. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42:432–45.

    CAS  PubMed  Google Scholar 

  77. Kienast O., Pirich C., Becherer A., Mitterhauser G., Dobrozemsky G., Dudczak R., Kletter K., Kurtaran A. Limited value of C11-methionine (MET)-PET for imaging of neuroendocrine tumors. Eur J Nucl Med 2003; 30:S203 [abstract].

    Google Scholar 

  78. Hoegerle S., Altehoefer C., Ghanem N., Brink I., Moser E., Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 28:64–71.

    CrossRef  CAS  PubMed  Google Scholar 

  79. Gourgiotis L., Sarlis N.J., Reynolds J.C., VanWaes C., Merino M.J., Pacak K. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-nuorodopamine positron emission tomography. J Clin Endocrinol Metab 2003; 88:637–41.

    CrossRef  CAS  PubMed  Google Scholar 

  80. Tonami N., Hisada K. 201-Tl scintigraphy in postoperative detection of thyroid cancer: a comparative study with 131 I. Radiology 1980; 136:461–4.

    CAS  PubMed  Google Scholar 

  81. Bleichrodt R.P., Vermey A., Piers D.A. de Langen Z.J. Early and delayed thallium 201 imaging: Diagnosis of patients with cold thyroid nodules. Cancer 1987; 60:2621–23.

    CAS  PubMed  Google Scholar 

  82. Burman K.D., Anderson J.H., Wartofsky L., Mong D.P., Jellenik J.J. Management of patients with thyroid carcinoma: application of thallium-201 scintigraphy and magnetic resonace imaging. J Nucl Med 1990; 31:1958–64.

    CAS  PubMed  Google Scholar 

  83. Murray I.P.C., Ell P.J. Nuclear medicine in clinical diagnosis and treatment. Churchill Livingstone. Second edition 1998: p832–p948.

    Google Scholar 

  84. Piers D.A., Sluiter W.J., Willemse P.H.B., Doorenbos H. Scintigraphy with 201 Tl for detection of thyroid cancer metastases. Eur J Nucl Med 1982; 7:515–7.

    CrossRef  CAS  PubMed  Google Scholar 

  85. Brendel A.J., Guyot M., Jeandot R., Lefort G., Manciet G. Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1988; 29:1515–20.

    CAS  PubMed  Google Scholar 

  86. Hoefnagel C.A., Delprat C.C., Marcuse H.R., de Vijlder J.J. Role of thallium-201 total body scintig-raphy in follow up of thyroid carcinoma. J Nucl Med 1986; 27:1854–57.

    CAS  PubMed  Google Scholar 

  87. Van Sorge-Van Boxtel R.A., Van Eck-Smit B.L., Goslings B.M. Comparison of serum thyroglobulin, 1311 and 201 Tl scintigraphy in the postoperative follow up of differentiated thyroid cancer. Nucl Med Commun 1993; 14:365–72.

    PubMed  Google Scholar 

  88. Dadparvar S., Krishna L., Brady L.W, Slizofski W.J., Brown S.J., Chevres A., Micaily B. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 1993; 71:3767–73.

    CAS  PubMed  Google Scholar 

  89. Charkes N.D., Vitti R.A., Brooks K. Thallium-201 SPECT increases detectability of thyroid cancer metastases. J Nucl Med 1990; 31:147–53.

    CAS  PubMed  Google Scholar 

  90. Shiga T., Tsukamoto E., Nakada K., Morita K., Kato T., Mabuchi M., Yoshinaga K., Katoh C., Kuge Y., Tamaki N. Comparision of (18)F-FDG, 131I-Na, and 201Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001;42: 414–19.

    CAS  PubMed  Google Scholar 

  91. Adalet I., Demirkale P., Unal S., Ouz H., Alagol F., Cantez S. Disappointing results with Tc-99m tetrofosmin for detecting medullary thyroid carcinoma metastases comparison with Tc-99m VDMSA and Tl-201. Clin Nucl Med 1999; 24: 678–83.

    CrossRef  CAS  PubMed  Google Scholar 

  92. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53:977–84.

    CAS  PubMed  Google Scholar 

  93. Seabold J., Gurll N., Schurrer M., Aktay R., Kirchner P.T. Comparison of 99mTc-methoxyisobutyl isonitrile and 201 Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. J Nucl Med 1999; 40:1434–40.

    CAS  PubMed  Google Scholar 

  94. Ng D., Sundram F., Sin A. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 2000; 41:631–5.

    CAS  PubMed  Google Scholar 

  95. Miyamoto S., Kasagai K., Misaki T., Alam M.S., Konishi J. Evaluation of technetium-99m-MIBI in metastatic differentiated thyroid carcinoma J Nucl Med 1997; 38:352–6.

    CAS  PubMed  Google Scholar 

  96. Rubello D., Mazzarotto R., Casara D. The role of technetium-99m methoxyisobutylisonitrile scintig-raphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27:431–40.

    CrossRef  CAS  PubMed  Google Scholar 

  97. Lind P., Gallowitsche H.J., Langsteger W., Kresnik E., Mikosh P., Gomez I. Technetium-99m-tetrafosmin whole body scintigrapy in the follow-up of differentiated thyroid carcinoma J Nucl Med 1997; 38:348–52.

    CAS  PubMed  Google Scholar 

  98. Unal S. Menda Y., Adalet I., Boztepe H. et al. Thallium-201, technctium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases J Nucl Med 1998; 39:1897–1902.

    CAS  PubMed  Google Scholar 

  99. Forsell-Aronsson E.B., Nilsson O., Bejegard S.A., Kolby L., Bernhardt P., Molne J., Hashemi S.H., Wangberg B., Tisell L.E., Ahlman H. 111 In-DTPA-D-Phe1-octreotidebinding and somatostatin receptor subtype in thyroid tumors. J. Nucl Med 2000; 41:636–42.

    Google Scholar 

  100. Ain K.B., Taylor K.D., Tofiq S., Venkatamaran G. Somatostatin receptor subtypes expression in human thyroid and thyroid carcinoma cell lines. J Clin End Metab 1997; 82:1857–62.

    CAS  Google Scholar 

  101. Forsell-Aronsson E.B., Nilsson O., Benjegard S.A., Kölby L., Ahlman H. 111In-DTPA-D-Phel-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 1999; 41:636–42.

    Google Scholar 

  102. Haslinghuis L.M., Krenning E.P., De Herder W.W, Reijs A.E., Kwekkeboom D.J. Somatostatin receptor scintigraphy in the follow-up of patents with differentiated thyroid cancer J Endocrinol Invest 2001; 24:415–22.

    CAS  PubMed  Google Scholar 

  103. Christian J.A., Cook G.J., Harmer C. Indium-111-labelled octreotide scintigraphy in the diagnosis and mangement of non-iodine avid metastatic carcinoma of the thyroid. BrJ Cancer 2003; 89:258–61.

    CAS  Google Scholar 

  104. Stokkel M.P.M., Reigman H.I.E., Verkooyen R.B.P., Smit J.W.A. Indium-111-Octreotide scinti-grapy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose 1-131 J Cancer Res Clin Oncol 2003; 129:287–94.

    CAS  PubMed  Google Scholar 

  105. Waldherr C., Schumacher T., Pless M., Crazollara A., Maecke H.R., Nitzsche E.U., Haldemann A., Mueller Brand J. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 2001; 22:673–78.

    CrossRef  CAS  PubMed  Google Scholar 

  106. Pacini F., Elisei R., Anelli S., Basolo F., Cola A., Pinchera A. Somatostatin in medullary thyroid cancer. In vitro and in vivo studies. Cancer 1989; 63:1189–95.

    CAS  PubMed  Google Scholar 

  107. Dorr U., Wurstlin S., Frank-Raue K., Raue F., Hehrmann R., Iser G., Scholz M., Guhl L., Buhr H.J., Bihl H. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. Horm Metab Res (Suppl) 1993; 27:48–55.

    CAS  Google Scholar 

  108. Berna L., Chico A., Matias-Guiu X., Mato E. Catafau A., Alonso C., Mora J., Mauricio D., Rodriguez-Espinosa J., Mari C., Flotats A., Martin J.C., Estorch M., Carrio I. Use of Somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 1998; 25:1482–88.

    CAS  PubMed  Google Scholar 

  109. Frank-Raue K., Bihl H., Dorr U., Buhr H., Ziegler R., Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma Clin Endocrinol 1995; 42: 31–7.

    CAS  Google Scholar 

  110. Arslan N., Ilgan S., Yuksel E., Serdengecti M., Bulakbasi N., Ugur O., Ozguven M.A. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 2001; 26:683–8.

    CrossRef  CAS  PubMed  Google Scholar 

  111. Sisson J.C., Frager M.S., Valk T.W., Gross M.D., Swanson D.P., Wieland D.M., Tobes M.C., Beierwaltes W.H., Thompson N.W. Scintigraphic localization of pheochromocytoma. N Eng J Med 1981; 305:12–7.

    CAS  Google Scholar 

  112. Jaquea Jr. S., Tobes M.C., Sisson J.C. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987; 47:3920–28.

    Google Scholar 

  113. Kimmig B.N. Radiotherapy for gastroenteropancreatic neuroendocrine tumors. Ann N Y Acad Sci 1994; 733:488–95.

    CAS  PubMed  Google Scholar 

  114. Henry J.P., Gasnier B., Desnos C., Scherman D., Krejci E., Massoulie J. The catecholamine transporter of adrenal medulla chromaffin granules. Ann N Y Acad Sci 1994; 733:185–92.

    CAS  PubMed  Google Scholar 

  115. Skowsky W.R., Wilf L.H. Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid. South Med J 1991; 84:636–41.

    CAS  PubMed  Google Scholar 

  116. Clarke S.E.M., Lazarus C.R., Wraight P., Sampson C., Maisey M.N. Pentavalent (99m-Tc) DMSA, (131-I) MIBG and (99m-Tc) MDP: an evaluation of three imaging techniques in patient with medullary carcinoma of the thyroid. J Nucl Med 1988; 29:33–8.

    CAS  PubMed  Google Scholar 

  117. Clarke S.E.M. (131I) metaiodobenzylguanidine therapy in medullar thyroid cancer: Guy’s Hospital experience. J Nucl Biol Med 1991; 35:323–6.

    CAS  PubMed  Google Scholar 

  118. Chauhan P.S., Babbar A., Kashyap R., Prakash R. Evaluation of a DMSA kit for instant preparation of 99mTc-(V)-DMSA for tumour and metastases scintigraphy. Int J Rad Appl Instrum B 1992; 19:825–30.

    CAS  PubMed  Google Scholar 

  119. Guerra U.P., Pizzocara C., Terzi A. Giubbini R., Maira G., Pagliaini R., Bestagno M. New tracers for the imaging of the medullary thyroid carcinoma. Nucl Med Comm 1989; 10:285–89.

    CAS  Google Scholar 

  120. Verga V., Muratori F., Sacco G., Banfi F., Libroia A. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. H Ford Hosp Med J 1989; 37:175–77.

    CAS  Google Scholar 

  121. Behr T.M., Gratz S., Markus P.M., Dunn R.M., Hufner M., Schauer A., Fischer M., Munz D.L., Becker H., Becker W. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997; 80:2436–57.

    CAS  PubMed  Google Scholar 

  122. Juweid M., Sharkey R.M., Behr T., Swayne L.C., Rubin A.D., Herskovic T., Hanley D., Markowitz A., Dunn R., Siegel. J., Kamal T., Goldenberg D.M. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996; 14:1209–17.

    CAS  PubMed  Google Scholar 

  123. Juweid M., Sharkey R.M., Swayne L.C., Goldenberg D.M. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery 1997; 122:1156–65.

    CrossRef  CAS  PubMed  Google Scholar 

  124. Barbet J., Peltier P., Bardet S., Vuillez J.P., Bachelot I. Denet S., Olivier P., Leccia F., Corcuff B., Huglo D., Proye C., Rouvier E., Meyer P., Chatal J.F. Radio immunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti CEA x anti-DTPA indium bispecific antibody. J Nucl Med 1998; 39:1172–78.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Groningen, Groningen, The Netherlands

    T. T. H. Phan & P. L. Jager

  2. Department of Endocrinology, University Hospital Groningen, Groningen, The Netherlands

    T. T. H. Phan, P. L. Jager, K. M. van Tol & T. P. Links

Authors
  1. T. T. H. Phan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. L. Jager
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. M. van Tol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. P. Links
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Osancor Biotech, Inc., Watford, WD17 3BY, Herts, UK

    Nadir R. Farid

Rights and permissions

Reprints and Permissions

Copyright information

© 2005 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

Phan, T.T.H., Jager, P.L., van Tol, K.M., Links, T.P. (2005). Thyroid Cancer Imaging. In: Farid, N.R. (eds) Molecular Basis of Thyroid Cancer. Cancer Treatment and Research, vol 122. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8107-3_18

Download citation

  • DOI: https://doi.org/10.1007/1-4020-8107-3_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8106-4

  • Online ISBN: 978-1-4020-8107-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

search

Navigation